Navigation Links
Rigel Announces Offering of 4,000,000 Shares of Common Stock
Date:1/24/2008

SOUTH SAN FRANCISCO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will initiate an offering of 4,000,000 shares of common stock pursuant to an automatically effective shelf registration statement on file with the Securities And Exchange Commission. It is currently anticipated that the underwriters will be granted an over-allotment option for an additional 600,000 shares.

Credit Suisse Securities (USA) LLC will be acting as the sole book-runner for the offering, with Thomas Weisel Partners LLC, Jefferies & Company, Inc. and Oppenheimer & Co. Inc. acting as co-managers.

A preliminary prospectus supplement relating to these securities will be filed with the Securities and Exchange Commission but remains subject to completion. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the prospectus supplement and related prospectus are delivered in final form. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities.

Copies of the preliminary prospectus supplement and related prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Prospectus Department, One Madison Avenue, New York, New York 10010-3629 (Telephone number 1-800-221-1037).

About Rigel (http://www.rigel.com)

We are a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases. Our goal is to file one new investigative new drug application in a significant indication each year. We have achieved this goal each year beginning in 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Our productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have internal product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis and thrombocytopenia, and cancer, as well as partnered product development programs relating to asthma and cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to complete a public offering and its strategy to further develop a portfolio of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "promising," "expects," "anticipates" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of preclinical and clinical trials, as well as other risks detailed from time to time in Rigel's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.430.3777

Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. Rigel Announces Third Quarter 2007 Financial Results
4. Weight Watchers Announces Fourth Quarter and Full Year 2007 Earnings Conference Call
5. Cochlear Americas Announces 2008 Graeme Clark Scholarship Winners
6. Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008
7. Avamere Health Systems Announces New President of Signature Home Health
8. The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America
9. Humanities Texas Announces Winners of The First Humanities Texas Award
10. NIH announces new initiative in epigenomics
11. BD Announces Results For First Fiscal Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... On May ... Aqua® Research Water Life Science® and international water advocate, was honored by Ashram, Inc. ... women in ancient Egypt who knelt on the banks of the Nile to fill ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... leader Mike Morrow-Fox . With over 20 years of experience in leading technology ... well as several years of university teaching, Morrow-Fox will be featured on ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... the launch of its brand equity product, Brandvantage. This breakthrough tool leaves ... landscape of modern consumer decision-making. The proprietary framework incorporates attitudes, behavior and ...
(Date:5/26/2016)... ... May 26, 2016 , ... In Madeira Beach Florida, a small ... single drawbridge, citizens formed an organization, Madeira Beach United, to oppose two development projects ... small town center to a high rise urban environment. , According to the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s ... to host their second pop-up shop for three consecutive weekends. The pop-up shop ... the Santa Barbara community, a community full of women who appreciate the most ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology: